Log in

NASDAQ:OGENOragenics Stock Price, Forecast & News

$0.75
-0.07 (-8.53 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.70
Now: $0.75
$0.80
50-Day Range
$0.51
MA: $0.57
$0.82
52-Week Range
$0.35
Now: $0.75
$0.92
Volume6.24 million shs
Average Volume2.41 million shs
Market Capitalization$41.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring chemical agent for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013; a license agreement with LPThera LLC to develop LPT3-04; and a license agreement Texas A&M University System for access to new homologs of the lantibiotic MU1140 and other lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.38 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OGEN
CUSIPN/A
CIKN/A
Phone813-286-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees6
Market Cap$41.57 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive OGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.

Oragenics (NASDAQ:OGEN) Frequently Asked Questions

How has Oragenics' stock been impacted by COVID-19 (Coronavirus)?

Oragenics' stock was trading at $0.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OGEN shares have increased by 25.2% and is now trading at $0.7509. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Oragenics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oragenics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Oragenics.

When is Oragenics' next earnings date?

Oragenics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Oragenics.

Has Oragenics been receiving favorable news coverage?

News stories about OGEN stock have trended negative this week, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oragenics earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term. View the latest news about Oragenics.

Who are some of Oragenics' key competitors?

What other stocks do shareholders of Oragenics own?

Who are Oragenics' key executives?

Oragenics' management team includes the following people:
  • Dr. Alan F. Joslyn, Pres, CEO & Director (Age 60)
  • Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 63)
  • Dr. Martin Handfield, Sr. VP of Discovery Research (Age 48)
  • Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant

What is Oragenics' stock symbol?

Oragenics trades on the NASDAQ under the ticker symbol "OGEN."

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $0.75.

How big of a company is Oragenics?

Oragenics has a market capitalization of $41.57 million. Oragenics employs 6 workers across the globe.

What is Oragenics' official website?

The official website for Oragenics is www.oragenics.com.

How can I contact Oragenics?

The company can be reached via phone at 813-286-7900.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.